Barber CA, Margolis K, Luepker RV, Arnett DK The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002). J Womens Health (Larchmt). 2004 Nov;13(9):975-85.
Burke GL, Edlavitch SA, Crow RS The effects of diagnostic criteria on trends in coronary heart disease morbidity: the Minnesota Heart Survey. J Clin Epidemiol. 1989;42(1):17-24.
Crow RS, Hannan PJ, Jacobs DR Jr, Lee SM, Blackburn H, Luepker RV Eliminating diagnostic drift in the validation of acute in-hospital myocardial infarction--implication for documenting trends across 25 years: the Minnesota Heart Survey. Am J Epidemiol. 2005 Feb 15;161(4):377-88.
Folsom AR, Sprafka JM, Luepker RV, Jacobs DR Jr Beliefs among black and white adults about causes and prevention of cardiovascular disease: the Minnesota Heart Survey. Am J Prev Med. 1988 May-Jun;4(3):121-7.
Gillum RF, Blackburn H, Feinleib M Current strategies for explaining the decline in ischemic heart disease mortality. J Chronic Dis. 1982;35(6):467-74.
Gillum RF, Liu KC Coronary heart disease mortality in United States blacks, 1940-1978: trends and unanswered questions. Am Heart J. 1984 Sep;108(3 Pt 2):728-32.
Iso H, Jacobs DR Jr, Goldman L Accuracy of death certificate diagnosis of intracranial hemorrhage and nonhemorrhagic stroke. The Minnesota Heart Survey. Am J Epidemiol. 1990 Nov;132(5):993-8.
Luepker RV, Herlitz J Differences in the treatment of acute myocardial infarction between regions of countries and the impact on prognosis. J Cardiovasc Risk. 1999 Apr;6(2):77-87. Review.
Luepker RV Current status of cholesterol treatment in the community: the Minnesota Heart Survey. Am J Med. 1997 Feb 17;102(2A):37-42.
Mascioli SR, Jacobs DR Jr, Kottke TE Diagnostic criteria for hospitalized acute myocardial infarction: the Minnesota experience. Int J Epidemiol. 1989 Mar;18(1):76-83.
McGovern PG, Herlitz J, Pankow JS, Karlsson T, Dellborg M, Shahar E, Luepker RV Comparison of medical care and one- and 12-month mortality of hospitalized patients with acute myocardial infarction in Minneapolis-St. Paul, Minnesota, United States of America and Göteborg, Sweden. Am J Cardiol. 1997 Sep 1;80(5):557-62.
Rosamond WD, Shahar E, Luepker RV Assessing medical history in coronary heart disease surveillance: agreement between contemporaneous and retrospective methods. Epidemiology. 1996 Jul;7(4):447-9.
Sprafka JM, Folsom AR, Burke GL, Edlavitch SA Prevalence of cardiovascular disease risk factors in blacks and whites: the Minnesota Heart Survey. Am J Public Health. 1988 Dec;78(12):1546-9.
Sprafka JM, Folsom AR, Burke GL, Edlavitch SA Prevalence of coronary heart disease risk factors in an urban black population: the Minnesota Heart Survey, 1985. Prev Med. 1988 May;17(3):321-34.
Sprafka JM, Folsom AR, Burke GL, Hahn LP, Pirie P Type A behavior and its association with cardiovascular disease prevalence in blacks and whites: the Minnesota Heart Survey. J Behav Med. 1990 Feb;13(1):1-13.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.